[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100421696":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":33,"locations":42,"responsibleParty":60,"collaborators":11,"id":63,"slug":11,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":11,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":11,"enrollmentInfo":71,"targetDuration":11,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":11,"overallStatus":45,"whyStopped":11,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"The University of Texas Health Science Center, Houston","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental group (Ketorolac)","EXPERIMENTAL",null,[13],"Drug: Ketorolac",{"label":15,"type":16,"description":11,"interventionNames":17},"Control Group","PLACEBO_COMPARATOR",[18],"Drug: Placebo",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Ketorolac","Ketorolac 0.5mg\u002Fkg will be administered intra-operatively at the conclusion of the case and 3 more doses scheduled every 8 hours in the first 24 hours post-operatively for a total of 4 doses of Ketorolac",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Placebo","0.9% Normal Saline will be administered intra-operatively at the conclusion of the case and 3 more doses scheduled every 8 hours in the first 24 hours post-operatively for a total of 4 doses of normal saline.",[15],[30],{"name":31,"affiliation":5,"role":32},"Matthew R Grieves, MD,MS,FACS","PRINCIPAL_INVESTIGATOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":11,"email":38},"Matthew R Greives, MD,MS,FACS","CONTACT","(713) 500-7275","Matthew.R.Greives@uth.tmc.edu",{"name":40,"role":36,"phone":11,"phoneExt":11,"email":41},"Tien Do, DO","Tien.Do@uth.tmc.edu",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"The University of Texas Health Science Center at Houston","RECRUITING","Houston","Texas","77030","United States",{"type":51,"coordinates":52},"Point",[53,54],-95.36327,29.76328,{"lat":54,"lon":53},[57,59],{"name":35,"role":36,"phone":58,"phoneExt":11,"email":38},"713-500-7275",{"name":40,"role":36,"phone":11,"phoneExt":11,"email":41},{"type":32,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"Matthew Greives","Associate Professor","100421696",false,"NCT04771156","Ketorolac in Palatoplasty","Ketorolac in Palatoplasty: A Randomized Blinded Controlled Trial.","Inclusion Criteria:\n\n-Patient with Cleft palate (Complete and incomplete), with or without cleft lip, unilateral or bilateral\n\nExclusion Criteria:\n\n* Syndromic Cleft Palate patients\n* Previous palatoplasty\n* Major unrepaired cardiac malformation\n* History of GI complications (GI Bleed, Gastric Ulceration)\n* History of Renal disorder\n* History of coagulopathy (As contraindication to NSAID use)\n* Feeding tube dependency\n* Patients whose parents refuse to consent to randomization","ALL","6 Months",{"count":72,"type":73},74,"ESTIMATED","INTERVENTIONAL",[76],"PHASE4","The purpose of this study is to see if the addition of IV Ketorolac to usual care multi-modal pain therapy compared to usual care will improve oral intake post-operatively",[79],"Cleft Lip and Palate","2026-02-17",{"date":82,"type":83},"2026-02-19","ACTUAL",{"date":85,"type":83},"2021-09-17",{"date":87,"type":73},"2027-04-01",{"name":5,"class":6},1]